258 related articles for article (PubMed ID: 37169182)
1. ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy.
Zhai J; Chen H; Wong CC; Peng Y; Gou H; Zhang J; Pan Y; Chen D; Lin Y; Wang S; Kang W; To KF; Chen Z; Nie Y; He HH; Sung JJ; Yu J
Gastroenterology; 2023 Aug; 165(2):445-462. PubMed ID: 37169182
[TBL] [Abstract][Full Text] [Related]
2. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
[TBL] [Abstract][Full Text] [Related]
3. METTL3 Inhibits Antitumor Immunity by Targeting m
Chen H; Pan Y; Zhou Q; Liang C; Wong CC; Zhou Y; Huang D; Liu W; Zhai J; Gou H; Su H; Zhang X; Xu H; Wang Y; Kang W; Kei Wu WK; Yu J
Gastroenterology; 2022 Oct; 163(4):891-907. PubMed ID: 35700773
[TBL] [Abstract][Full Text] [Related]
4. Targeting m
Bao Y; Zhai J; Chen H; Wong CC; Liang C; Ding Y; Huang D; Gou H; Chen D; Pan Y; Kang W; To KF; Yu J
Gut; 2023 Aug; 72(8):1497-1509. PubMed ID: 36717220
[TBL] [Abstract][Full Text] [Related]
5. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.
Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107
[TBL] [Abstract][Full Text] [Related]
6. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.
Wang L; Zhu L; Liang C; Huang X; Liu Z; Huo J; Zhang Y; Zhang Y; Chen L; Xu H; Li X; Xu L; Kuang M; Wong CC; Yu J
J Hepatol; 2023 Nov; 79(5):1185-1200. PubMed ID: 37459919
[TBL] [Abstract][Full Text] [Related]
7. N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.
Zhang Z; Wang L; Zhao L; Wang Q; Yang C; Zhang M; Wang B; Jiang K; Ye Y; Wang S; Shen Z
Clin Transl Med; 2022 Aug; 12(8):e940. PubMed ID: 35979628
[TBL] [Abstract][Full Text] [Related]
8. M
Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
[TBL] [Abstract][Full Text] [Related]
9. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment.
Li N; Kang Y; Wang L; Huff S; Tang R; Hui H; Agrawal K; Gonzalez GM; Wang Y; Patel SP; Rana TM
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20159-20170. PubMed ID: 32747553
[TBL] [Abstract][Full Text] [Related]
10. m
Tang B; Yang Y; Kang M; Wang Y; Wang Y; Bi Y; He S; Shimamoto F
Mol Cancer; 2020 Jan; 19(1):3. PubMed ID: 31906946
[TBL] [Abstract][Full Text] [Related]
11. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m
Zhou L; Jiang J; Huang Z; Jin P; Peng L; Luo M; Zhang Z; Chen Y; Xie N; Gao W; Nice EC; Li JQ; Chen HN; Huang C
Mol Cancer; 2022 Aug; 21(1):168. PubMed ID: 35986274
[TBL] [Abstract][Full Text] [Related]
13. N
Zhu Z; Qian Q; Zhao X; Ma L; Chen P
Gene; 2020 Mar; 731():144348. PubMed ID: 31927006
[TBL] [Abstract][Full Text] [Related]
14. Wnt/β-Catenin Signaling Activation beyond Robust Nuclear β-Catenin Accumulation in Nondysplastic Barrett's Esophagus: Regulation via Dickkopf-1.
Lyros O; Rafiee P; Nie L; Medda R; Jovanovic N; Otterson MF; Behmaram B; Gockel I; Mackinnon A; Shaker R
Neoplasia; 2015 Jul; 17(7):598-611. PubMed ID: 26297437
[TBL] [Abstract][Full Text] [Related]
15. Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m
Zhang L; Su X
Cell Oncol (Dordr); 2022 Jun; 45(3):355-365. PubMed ID: 35579750
[TBL] [Abstract][Full Text] [Related]
16. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
Qu S; Jin L; Huang H; Lin J; Gao W; Zeng Z
BMC Cancer; 2021 Jun; 21(1):686. PubMed ID: 34112124
[TBL] [Abstract][Full Text] [Related]
17. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
[TBL] [Abstract][Full Text] [Related]
18. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m
Chen Y; Zhao Y; Chen J; Peng C; Zhang Y; Tong R; Cheng Q; Yang B; Feng X; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2020 Aug; 19(1):123. PubMed ID: 32772918
[TBL] [Abstract][Full Text] [Related]
19. ALKBH5/YTHDF2-mediated m6A modification of circAFF2 enhances radiosensitivity of colorectal cancer by inhibiting Cullin neddylation.
Shao Y; Liu Z; Song X; Sun R; Zhou Y; Zhang D; Sun H; Huang J; Wu C; Gu W; Zheng X; Jiang J
Clin Transl Med; 2023 Jul; 13(7):e1318. PubMed ID: 37381158
[TBL] [Abstract][Full Text] [Related]
20. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]